Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Mar;15(3):135-136.
doi: 10.1038/nrgastro.2017.184. Epub 2018 Jan 10.

Pancreatic cancer: Next-generation algorithms for neoantigen selection

Alexander Hopkins  1 , Elizabeth Jaffee  1
Affiliations
Comment

Pancreatic cancer: Next-generation algorithms for neoantigen selection

Alexander Hopkins et al. Nat Rev Gastroenterol Hepatol. 2018 Mar.

Abstract

Predicting clinical outcomes in cancer using neoantigen burden is imperfect because current algorithms use only the binding affinity of putative neoantigens to HLA. A new study models pancreatic tumour response through a deeper understanding of tumour immunology, providing new tools for identifying neoantigens and characteristics that define their quality.

PubMed Disclaimer

Figures

Figure 1 |
Figure 1 |. Tumour evolution in response to immune pressure in pancreatic cancer.
Tumour evolution is modelled using the quantity model (part a), in which survival is a function of the number of HLA binding neoantigens in each tumour clone, or the quality model (part b), in which the survival of a clone depends on high-quality neoantigens, identified by their ability to bind HLA as well as their similarity to known pathogen-derived antigens.
See this image and copyright information in PMC

Comment on

  • Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.
    Balachandran VP, Łuksza M, Zhao JN, Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U, Senbabaoglu Y, Wells DK, Cary CIO, Grbovic-Huezo O, Attiyeh M, Medina B, Zhang J, Loo J, Saglimbeni J, Abu-Akeel M, Zappasodi R, Riaz N, Smoragiewicz M, Kelley ZL, Basturk O; Australian Pancreatic Cancer Genome Initiative; Garvan Institute of Medical Research; Prince of Wales Hospital; Royal North Shore Hospital; University of Glasgow; St Vincent’s Hospital; QIMR Berghofer Medical Research Institute; University of Melbourne, Centre for Cancer Research; University of Queensland, Institute for Molecular Bioscience; Bankstown Hospital; Liverpool Hospital; Royal Prince Alfred Hospital, Chris O’Brien Lifehouse; Westmead Hospital; Fremantle Hospital; St John of God Healthcare; Royal Adelaide Hospital; Flinders Medical Centre; Envoi Pathology; Princess Alexandria Hospital; Austin Hospital; Johns Hopkins Medical Institutes; ARC-Net Centre for Applied Research on Cancer; Gönen M, Levine AJ, Allen PJ, Fearon DT, Merad M, Gnjatic S, Iacobuzio-Donahue CA, Wolchok JD, DeMatteo RP, Chan TA, Greenbaum BD, Merghoub T, Leach SD. Balachandran VP, et al. Nature. 2017 Nov 23;551(7681):512-516. doi: 10.1038/nature24462. Epub 2017 Nov 8. Nature. 2017. PMID: 29132146 Free PMC article.

References

    1. Mehnert JM et al. The challenge for development of valuable immuno-oncology biomarkers. Clin. Cancer Res. 23, 4970–4979 (2017). - PMC - PubMed
    1. Le DT et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015). - PMC - PubMed
    1. Sahin U et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222–226 (2017). - PubMed
    1. Balachandran VP et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 10.1038/nature24462 (2017). - DOI - PMC - PubMed
    1. Zitvogel L, Ayyoub M, Routy B & Kroemer G Microbiome and anticancer immunosurveillance. Cell 165, 276–287 (2016). - PubMed